A next-generation COVID-19 mucosal vaccine is set to be a gamechanger not only when delivering the vaccine itself, but also for people who are needle-phobic. (Credit: Griffith University)

A next-generation COVID-19 mucosal vaccine is set to be a gamechanger not only when delivering the vaccine itself, but also for people who are needle-phobic. New research has been testing the efficacy of delivering a COVID-19 vaccine via the nasal passages.

This is a live attenuated intranasal vaccine, called CDO-7N-1, designed to be administered intranasally, thereby inducing potential mucosal immunity as well as systemic immunity with just a single dose. The vaccine induces strong memory responses in the nasal mucosa offering long-term protection for up to a year or more.

Live-attenuated vaccines comprise the entire virus thereby providing broad immunity, in contrast to a single antigen which is used in many other vaccine platforms. Unlike the mRNA vaccine which targets only the spike protein, CDO-7N-1 induces immunity to all major SARS-CoV-2 proteins and is highly effective against all major variants to date.

Source 

Topics:
Drug Delivery Medical Product Development

More From SAE Media Group

Medical Design Briefs INSIDER
Single-Dose COVID-19 Nanoparticle Vaccine Could Be Stored at Room Temperature
Related article image
Medical Design Briefs INSIDER
Ultrapotent COVID-19 Vaccine Could Be Game Changer
Related article image
Medical Design Briefs INSIDER
Hybrid Microneedle Array Platform Delivers Vaccines Directly into Skin
Related article image
Medical Design Briefs
NIH: Experimental Coronavirus Vaccine Is Safe and Produces Immune Response
Related article image